Kristi L. Manjarrez

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN

Laura Q.M. Chow, Chihiro Morishima, Keith D. Eaton et al. · Clinical Cancer Research · 2016 · 126 citations

Medicine, Oncology, Pharmacology +17

Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck

Robert L. Ferris, Nabil F. Saba, Barbara J. Gitlitz et al. · JAMA Oncology · 2018 · 111 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study

Bradley J. Monk, Mark F. Brady, Carol Aghajanian et al. · Annals of Oncology · 2017 · 93 citations · Full text

Medicine, Oncology, Pharmacology +17

A Phase I Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX-2337 in Adult Subjects with Advanced Solid Tumors or Lymphoma

Donald W. Northfelt, Ramesh K. Ramanathan, Peter A. Cohen et al. · Clinical Cancer Research · 2014 · 68 citations

Medicine, Oncology, Pharmacology +16

Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337)

Gregory N. Dietsch, Tressa D. Randall, Raphaël Gottardo et al. · Clinical Cancer Research · 2015 · 39 citations

Life Sciences, Immunology, Pharmacology +17